These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29782995)

  • 21. Agitation and psychosis in dementia.
    Ballard C
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):913-7. PubMed ID: 17974863
    [No Abstract]   [Full Text] [Related]  

  • 22. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.
    Lopez OL; Becker JT; Chang YF; Sweet RA; Aizenstein H; Snitz B; Saxton J; McDade E; Kamboh MI; DeKosky ST; Reynolds CF; Klunk WE
    Am J Psychiatry; 2013 Sep; 170(9):1051-8. PubMed ID: 23896958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates.
    Marcinkowska M; Śniecikowska J; Fajkis N; Paśko P; Franczyk W; Kołaczkowski M
    CNS Drugs; 2020 Mar; 34(3):243-268. PubMed ID: 32052375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haloperidol for agitation in dementia.
    Lonergan E; Luxenberg J; Colford J
    Cochrane Database Syst Rev; 2001; (4):CD002852. PubMed ID: 11687166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
    Kurlan R; Cummings J; Raman R; Thal L;
    Neurology; 2007 Apr; 68(17):1356-63. PubMed ID: 17452579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
    Workman RH; Orengo CA; Bakey AA; Molinari VA; Kunik ME
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):594-7. PubMed ID: 9447503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical perspectives on atypical antipsychotics for treatment of agitation.
    Caine ED
    J Clin Psychiatry; 2006; 67 Suppl 10():22-31. PubMed ID: 16965192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological treatment of psychotic agitation.
    Currier GW; Trenton A
    CNS Drugs; 2002; 16(4):219-28. PubMed ID: 11945106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.
    Creese B; Da Silva MV; Johar I; Ballard C
    Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders.
    Agid O; Kapur S; Warrington L; Loebel A; Siu C
    Schizophr Res; 2008 Jul; 102(1-3):241-8. PubMed ID: 18495436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Injectable atypical antipsychotics for agitation in borderline personality disorder.
    Pascual JC; Madre M; Soler J; Barrachina J; Campins MJ; Alvarez E; Pérez V
    Pharmacopsychiatry; 2006 May; 39(3):117-8. PubMed ID: 16721704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
    Franco KN; Messinger-Rapport B
    J Am Med Dir Assoc; 2006 Mar; 7(3):201-2. PubMed ID: 16503315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of behavioral disturbances and psychosis associated with dementia.
    Lochhead JD; Nelson MA; Maguire GA
    Psychiatr Pol; 2016; 50(2):311-22. PubMed ID: 27288676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
    Daniel DG; Potkin SG; Reeves KR; Swift RH; Harrigan EP
    Psychopharmacology (Berl); 2001 May; 155(2):128-34. PubMed ID: 11401000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
    Lesem MD; Zajecka JM; Swift RH; Reeves KR; Harrigan EP
    J Clin Psychiatry; 2001 Jan; 62(1):12-8. PubMed ID: 11235922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases: evidence about efficacy and safety.
    Weintraub D; Katz IR
    Psychiatr Clin North Am; 2005 Dec; 28(4):941-83, ix-x. PubMed ID: 16325736
    [No Abstract]   [Full Text] [Related]  

  • 38. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics.
    Lawlor BA
    J Clin Psychiatry; 2004; 65 Suppl 11():5-10. PubMed ID: 15264965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current attitudes regarding treatment of agitation and psychosis in dementia.
    Serby MJ; Roane DM; Lantz MS; Cohen AJ; Turok A; Perlis TE
    Am J Geriatr Psychiatry; 2009 Feb; 17(2):174. PubMed ID: 19155750
    [No Abstract]   [Full Text] [Related]  

  • 40. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.